Aerie Pharmaceuticals, Inc., a prominent player in the ophthalmic pharmaceutical industry, is headquartered in the United States. Founded in 2008, the company has rapidly established itself as a leader in developing innovative therapies for eye diseases, particularly glaucoma and retinal disorders. Aerie's core products, including the unique eye drops Rhopressa® and Rocklatan®, are designed to lower intraocular pressure, setting them apart in a competitive market. With a strong focus on research and development, Aerie has achieved significant milestones, including successful product launches and expanding its operational footprint across North America and Europe. The company’s commitment to advancing eye care has positioned it favourably within the industry, earning recognition for its contributions to improving patient outcomes and enhancing the quality of life for those affected by vision-related conditions.
We don't have data for Aerie Pharmaceuticals, Inc., but we can show you information about their parent organization instead.
View parent company